| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | 5.2 | 4.6 |
| Gross profit | 4.3 | 3.8 |
| Net income | -5.5 | -4.7 |
| EPS (diluted, $ a share) | $-0.86 | $-0.74 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +12.5% |
|---|---|
| Gross margin | 82.1% |
| Operating margin | -103.6% |
10-K filed with the SEC, OTC: ZEOX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zeo ScientifiX, Inc.: key numbers
- Share price
- $0.7960Close, Nov 13
- Market cap
- $6.24M
- Shares outstanding
- 7.84MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zeo ScientifiX, Inc.
All →Zeo ScientifiX Business Update
Zeo ScientifiX announced that its manufacturing facility is the first to achieve Quality Management Systems (QMS) Certification under a newly established program by the Association for the Advancement of Blood & Biotherapies (AABB). This certification serves as an independent validation of the company's manufacturing quality and operational discipline in the regenerative medicine sector.
- Counterparty
- Association for the Advancement of Blood & Biotherapies
Zeo ScientifiX Partnership with Pluri Inc.
Zeo ScientifiX entered into a definitive strategic agreement with Pluri Inc. to expand U.S. manufacturing and commercialization of regenerative medicine products. As part of the license-for-equity transaction, Pluri will grant ZEO an exclusive license to its proprietary 3D cell expansion platform in exchange for a 41% equity stake in ZEO and a share swap involving 4% of each company's outstanding stock.
- Counterparty
- Pluri Inc.
Zeo ScientifiX Partnership with Pluri Inc.
Zeo ScientifiX and Pluri Inc. entered into a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine and aesthetics. The transaction involves a share exchange that will result in Pluri owning 50% of ZEO, combining Pluri's 3D cell-expansion technology with ZEO's biologics manufacturing and physician sales network.
- Counterparty
- Pluri Inc.
Zeo ScientifiX Other 8-K Filing
Zeo ScientifiX, Inc. has changed its fiscal year end from October 31 to June 30, effective for the fiscal year ending June 30, 2026. The company will file a transition report on Form 10-KT for the eight-month period from November 1, 2025, through June 30, 2026.
Zeo ScientifiX Business Update
Zeo ScientifiX announced plans to expand its commercial and provider-support operations into Georgia and Tennessee. The move follows the enactment of new state laws in both jurisdictions that establish frameworks for stem cell and regenerative medicine therapies. The expansion aims to support healthcare providers with biologics, education, and implementation support as they navigate these evolving state-level regulatory environments.